Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Cytosorbents Corp (CTSO)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $37.1M | $35.6M | $31.1M | $34.7M | $43.2M | $41.0M | $24.9M | $22.5M | $15.2M | $8.2M | $4.8M | $4.1M | $2.4M | $1.3M | $36,078 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Gross profit | $26.5M | $24.9M | $22.0M | $20.7M | $32.1M | $30.0M | $17.6M | $15.0M | $9.6M | $5.6M | $2.6M | $2.0M | $511,102 | $1.0M | $24,318 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Research & development | — | — | $15.7M | $15.1M | $16.4M | $8.8M | $12.1M | $7.7M | $3.2M | $4.1M | $3.9M | $2.4M | $1.7M | $2.5M | $2.9M | $1.8M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating expenses | $41.2M | $41.3M | $53.9M | $52.3M | $54.9M | $40.3M | $36.6M | $30.6M | $19.5M | $17.1M | $11.9M | $8.9M | $5.2M | $4.5M | $4.5M | $2.8M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | −$14.7M | −$16.5M | −$31.9M | −$31.5M | −$22.7M | −$10.4M | −$19.0M | −$15.6M | −$9.8M | −$11.5M | −$9.3M | −$6.9M | −$4.7M | −$3.5M | −$4.4M | −$2.8M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDAderived | −$13.5M | −$15.1M | −$30.5M | −$30.6M | −$22.0M | −$9.7M | −$18.4M | −$15.2M | −$9.6M | −$11.3M | −$9.2M | −$6.8M | −$4.6M | −$3.4M | −$4.4M | −$2.8M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net income | −$8.2M | −$20.7M | −$29.2M | −$32.8M | −$24.6M | −$7.8M | −$19.3M | −$17.2M | −$8.5M | −$11.8M | −$9.5M | −$9.3M | −$4.7M | −$3.7M | −$5.5M | −$2.9M | −$2.7M | −$3.0M | −$3.4M | −$76.7M | −$3.7M | −$1.1M | −$6.0M | −$11.9M | −$15.4M | −$3.1M | −$10.8M | −$1.9M | −$5.3M |
| Basic EPSper diluted share | -$0.13 | -$0.38 | -$0.65 | -$0.75 | -$0.57 | -$0.20 | -$0.60 | -$0.56 | -$0.32 | -$0.46 | -$0.38 | -$1.29 | -$0.75 | -$0.03 | -$0.05 | -$0.05 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPSper diluted share | -$0.13 | -$0.38 | -$0.65 | -$0.75 | -$0.57 | -$0.20 | -$0.60 | -$0.56 | -$0.32 | -$0.46 | -$0.38 | -$1.29 | -$0.75 | -$0.03 | -$0.05 | -$0.05 | — | — | — | — | — | — | — | — | — | — | — | — | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 15, 2026Form 4 | MARIANI PETER JChief Financial Officer | BuyCommon Stock | 100.0K | $0.44 | $44.0K | 638.1K |
| Jun 15, 2026Form 4 | Chan Phillip P.Chief Executive Officer | BuyCommon Stock | 10.3K | $0.43 | $4.4K | 1.74M |
| Jun 12, 2026Form 4 | Chan Phillip P.Chief Executive Officer | BuyCommon Stock | 251.1K | $0.40 | $100.5K | 1.73M |
| Dec 13, 2024Form 4 | MARIANI PETER JChief Financial Officer | BuyCommon Stock | 20.0K | $0.96 | $19.2K | 401.4K |
| Dec 12, 2024Form 4 | MARIANI PETER JChief Financial Officer | BuyCommon Stock | 20.0K | $0.89 | $17.8K | 381.4K |